Previous 10 | Next 10 |
Thesis: Gilead Sciences ( GILD ) has been relatively stagnant since the end of FY15 with the fall of its Hepatitis C ((HCV)) portfolio sales. Gilead's HCV sales for FY15 reached levels near $19 billion; current trailing 12-month HCV sales now sit a bit over $3 billion. However, Gilead has ...
By Callum Turcan Data by YCharts Image Shown: Shares of Gilead Sciences Inc. ( GILD ) have come under immense pressure since mid-2015, however, with the company's revenues now stabilizing Gilead's outlook is getting brighter. Gilead Sciences Inc. recently delivered some good news as ...
Gilead Sciences (NASDAQ: GILD ) is an $80 billion American biotechnology company that researches, develops, and commercializes drugs. The company is renowned for curing Hepatitis C and its leading HIV treatments. As we’ll see throughout this article, Gilead Sciences’ impressive ...
Gilead Sciences ( GILD ) has been a terrible investment in the last five years, in which the stock kept declining. During the last twelve months, the stock was more or less stable and was trading in a rather narrow 52-week range (between $60.89 and $70.50). And aside from the quarterly dividen...
Source (Shutterstock/Liya Graphics) Introduction Gilead Sciences ( GILD ) was positioned to be the poster child of Trump's plan to eradicate HIV, as outlined in my previous article . Like almost all outbreaks including the Wuhan coronavirus, the only effective way to complete...
Investing in biotech stocks might just be a great idea. The industry as a whole -- as measured by the SPDR S&P Biotech ETF Index -- provided a return of 45.5% over the past three years, narrowly outperforming the S&P 500 and its 44.5% return over the same period. Of course, there a...
Safety First: NASCAR driver Johanna Long and her helmet (Credit: Gearheads ) Revisiting Our Revised Security Selection Method Since June 2017, I've run a Marketplace service which has an " investing with a helmet on " approach: I present concentrated portfolios where each security is he...
Gilead Tests Potential Ebola Treatment for Coronavirus Gilead Sciences ( GILD ) announced that it is currently in the process of evaluating the use of its experimental Ebola candidate, Nuc inhibitor GS-5734, for treating 2019-nCov infection. The company is currently engaged in active discu...
December was yet again a strong month for the market as the S&P500 gained another 2.37%. My portfolio gained only 0.64% as I am continuously lowering my portfolio risk by adding more defensive stocks. However, 2020 started strong for me as I gained more than 2%.My portfolio is still based...
Gilead Sciences (NASDAQ: GILD ) is an American biotechnology that researches, develops, and commercializes drugs. The company is best known for curing Hepatitis C, however, they have a portfolio of impressive assets. As we’ll see throughout this article, the company’s impressive...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 21:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging resul...